Interesting that Long COVID sufferers are not being sorted into cohorts by vaccination status, and that neither the Ivermectin nor Hydroxychloroquine protocols are apparently even being considered for study, only Paxlovid. Metformin has shown promise, also (English study mentioned in the article), but like IVM and HCQ, has been in production for years, and there is no pile of money to be made.